# KEY INFORMATION DOCUMENT – ORDINARY SHARES

Purpose	This document provides you with key information about this investment product. It is not marketing material. This information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.
Product	o purchase a product that is not simple and may be difficult to understand.  Ordinary shares in Ventus 2 VCT PLC, ISIN GB00B0WCHT14 www.ventusvct.com)
T T Gudet	managed by Temporis Capital Limited, authorised and regulated by the Financial Conduct Authority, FRN 763725 ( <a href="https://www.temporiscapital.com">www.temporiscapital.com</a> )
What is this pro	duct?
Туре	Ventus 2 VCT PLC is a company (the "Company") listed on the London Stock Exchange (LSE). The Company has 3 different share classes, <b>Ordinary shares</b> , C shares and D shares which can be bought and sold through a stockbroker. Typically, at any given time on any given day, the price you pay for a share will be higher than the price at which you could sell it. (This is referred to as the bid-offer spread.)  The Company is a Venture Capital Trusts (VCTs). For eligible VCT shareholders (i.e., UK Residents aged over 18 years), there is no liability to tax on dividends and no Capital Gains Tax on realised gains from the sale of shares. An investment limit of £200,000 per person per tax year applies.  The net asset value (NAV) for each share class is calculated every 6 months by reference to the underlying assets of the company. These are operational sites generating electricity from renewable sources – wind, hydroelectricity and landfill gas.
	The price quoted on the LSE will either be at a discount or premium to the NAV of that share class.  The Company has approval under its constitutional documents to borrow up to
	10% of its net assets. Currently it does not, and nor does it intend to, borrow.
Objectives	Each share class has a clear dividend objective, aimed at delivering a long term sustainable tax-free yield to shareholders.
Intended retail investor	These shares are intended to be held over the longer term, providing its shareholders with an opportunity to receive a sustainable tax-free income and capital growth over the longer term. (See Other Relevant Information.)
What are the ris	sks and what could I get in return?
Summary Risk Indicator	Presentation of Summary Risk Indicator (SRI)  1 2 3 4 5 6 7
	Lower risk Higher risk

The calculation of this SRI assumes that you keep your shares for 5 years. The actual risk can vary significantly if you sell your shares at an early stage and you may get back less than you paid. You may not be able to sell your shares easily or you may have to sell at a price that significantly impacts on how much you get back.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because the shares are thinly traded with no ready purchaser (market maker) to buy your shares from you.

We have classified this product as 3 out of 7, which is a medium-low risk class. This rates the potential losses from future performance at a medium-low level, and poor market conditions could impact your ability to sell your shares.

Your capital is at risk as the value of investments may go down as well as up and therefore, you may not get back the amount originally invested. Past performance is not a guide to future performance.

Performance
Scenarios

	Performance scenarios - based on £10,000 invested	5 years (=recommended holding period)
Stress scenario	What you might get back after costs (£)	9,651
	Average return each year	-0.71%
Unfavourable scenario	What you might get back after costs (£)	7,036
	Average return each year	-6.79%
Moderate scenario	What you might get back after costs (£)	9,718
	Average return each year	-0.57%
Favourable scenario	What you might get back after costs (£)	13,535
	Average return each year	6.24%

This table shows the money you could get back over the next 5 years, under different scenarios, assuming that you invest £10,000.

The scenarios shown illustrate how your investment could perform. You can compare them with the scenarios of other products.

The scenarios presented are an estimate of future performance based on evidence from the past on how the value of this investment varies, and are not an exact indicator. What you will get will vary depending on how the market performs and how long you keep the investment.

The stress scenario shows what you might get back in extreme market circumstances, and does not take into account the situation where you cannot sell your shares easily or you may have to sell at a price that significantly impacts on how much you get back.

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

## What happens if the Company is unable to pay out?

As a shareholder in the Company, the value of your shares, and the amount that you receive if you decide to sell your shares, is not in any way guaranteed. In the event that the Company is unable to pay out, you would not be able to make a claim to the Financial Services Compensation Scheme (FSCS).

### What are the costs?

The Reduction in Yield (RIY) shows what **impact the total costs** you pay will have on the investment return that you might get. The total costs take into account one-off, ongoing and incidental costs.

The amounts shown here are the cumulative costs of the product itself, for 3 different holdings periods. They include potential early exit penalties. The figures assume you invest £10,000. The figures are estimates and may change in the future.

Costs over time			
Investment (£10,000)			
Scenarios	If you cash in after 1	If you cash in after 3	If you cash in after 5
	year	years	years
Total costs	386	1,058	1,731
Impact on return	3.88%	3.59%	3.56%
(RIY) per year			

### The table below shows:

- the impact each year of the different types of costs on the investment return you might get at the end of the recommended holding period
   the meaning of the different cost categories
- **Composition of Costs** This table shows the impact on return per year One off costs 0.5% Stamp Duty Reserve Tax (SDRT) is Entry costs Exit costs 0% payable on share purchases. There may be additional one-off costs paid directly by an investor to an adviser. Ongoing costs Portfolio transaction 0.00% The impact of the costs of us buying and selling underlying assets. costs 3.36% The impact of the costs of managing Other ongoing costs and administering the assets Incidental costs Performance fees 0% The impact of the performance fee. We take this from your investment if the gross return exceeds its agreed benchmark. Carried interests 0% Not applicable

### How long should I hold my shares, and can I sell my shares early?

Recommended holding period: 5 years.

Refer to "What are the risks and what can I get in return?"
---

You can sell your shares at any time, but you may get back less than you paid. You may not be able to sell your shares easily or you may have to sell at a price that significantly impacts on how much you get back.

# How can I complain?

Date of

production

17 December 2020

As a shareholder in Ventus 2 VCT PLC, if you are dissatisfied with the portfolio and risk management performed by its investment manager, Temporis Capital Limited, you should refer to its website – <a href="https://www.temporiscapital.com">www.temporiscapital.com</a>.

# This information has been prepared on the basis that you hold your shares for a 5-year period. It is not a recommendation that you hold your shares for 5 years. It should be noted that the Company will be holding a continuation vote in 2021, for which shareholders will be asked to consider whether or not the Company should continue in its current format. The cost, performance and risk calculations included in this KID follow the methodology prescribed by EU rules.